Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparative Efficacy and Safety of Dual Versus Triple Lipid-Lowering Therapies (Rosuvastatin/Ezetimibe, Bempedoic Acid/Ezetimibe, and Rosuvastatin/Ezetimibe/Bempedoic Acid ) in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol

NCT07255820 is registered in ClinicalTrials.gov with Bahria University as lead sponsor.

NCT NCT07255820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07255820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparative Efficacy and Safety of Dual Versus Triple Lipid-Lowering Therapies (Rosuvastatin/Ezetimibe, Bempedoic Acid/Ezetimibe, and Rosuvastatin/Ezetimibe/Bempedoic Acid ) in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol
Lead sponsor
Bahria University
Phase
Phase 4
Overall status
Completed
Start date
January 1, 2026
Completion date
June 30, 2026
Enrollment
126 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypercholesterolemia / elevated ldl cholesterol, type 2 diabetes mellitus